Similarly, studies in mice reported reduced tumor growth when cyclin-dependent kinase 4/6 (CDK4/6) drugs were administered in a time-dependent manner, showing higher efficacy in a morning dosing regimen compared to nighttime dosing [44]. Here, CDK4 is linked to neoplasm.